BCM
FPRX

BlueCrest Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

BlueCrest Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,868
Closed -$567K – 1183
2017
Q3 		$567K Buy
+13,868
New +$435K 0.02% 480
2017
Q2 		– Sell
-7,024
Closed -$254K – 1179
2017
Q1 		$254K Buy
+7,024
New +$310K 0.01% 565

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlueCrest Capital Management's FPRX Position: Q4 2017 in Review

BlueCrest Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2017, closing a stake of 13,868 shares — an estimated $567K sold.

BlueCrest Capital Management first reported a position in FPRX in Q1 2017 and held it in 2 quarters. The position peaked at $567K in Q3 2017. 137 funds tracked by Wall St. Rank hold FPRX as of Q4 2017.

  • BlueCrest Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 13,868 Five Prime Therapeutics, Inc. shares in Q4 2017, an estimated $567K.
  • BlueCrest Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2017 and held it in 2 quarters.
  • BlueCrest Capital Management's Five Prime Therapeutics, Inc. position peaked at $567K in Q3 2017.
  • 137 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2017.

Based on BlueCrest Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.